Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study

Abstract

ObjeCtivesTo determine the real world safety of dabigatran or rivaroxaban compared with warfarin in terms of gastrointestinal bleeding.

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…U pacjentów otrzymujących dabigatran w dawce 110 mg 2 razy/dobę [490] lub apiksaban w dawce 5 mg 2 razy/dobę [319] ryzyko krwawienia z przewodu pokarmowego było natomiast podobne jak podczas stosowania warfaryny. Najnowsze analizy obserwacyjne nie potwierdziły tych wyników, wskazując na mniejszy efekt [396,492,493]. U pacjentów, u których zidentyfikowano i wyeliminowano źródło krwawienia, można powrócić do OAC.…”

2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS

“…319 Recent observational analyses do not replicate these findings, suggesting a smaller effect. 396,492,493 In patients in whom the source of bleeding has been identified and corrected, OAC can be reinitiated. This also appears true for patients who have had an intracranial haemorrhage, once modifiable bleeding risk factors (e.g.…”

Systematic Review of Medicine-Related Problems in Adult Patients with Atrial Fibrillation on Direct Oral Anticoagulants

“…The study duration ranged from 10 ( Thorne et al, 2014) to 23 (Gorst-Rasmussen et al, 2015) months and the sample sizes ranged from 150 (Hu et al, 2015) to 27,514 (Martinez et al, 2016) subjects. The data collection method involved electronic medical record reviews (Donaldson and Norbeck, 2013;Lee et al, 2013;Cutler et al, 2014;Ho et al, 2014;Monteagudo et al, 2015;Martinez et al, 2016), electronic national database searches Larsen et al, 2013;Graham et al, 2014;Beyer-Westendorf et al, 2015;Chang et al, 2015;Gorst-Rasmussen et al, 2015;Hu et al, 2015;Chan et al, 2016;Forslund et al, 2016;Nishtala et al 2016), questionnaires (Thorne et al, 2014;Hu et al, 2015), and a reporting system (Andreica and Grissinger, 2015). The settings of these studies were in hospitals, primary care centres, or both.…”

“…The findings of this review suggest that no studies defined MRPs involving DOACs, and ADRs and ADEs were used interchangeably. Four of the retrospective studies investigated ADRs (Larsen et al, 2013;Graham et al, 2014;Chang et al, 2015;Nishtala et al, 2016], one investigate medication errors (Andreica and Grissinger, 2015), one investigated persistence (Forslund et al, 2016), and two investigated adherence (Lee et al, 2013;Cutler et al, 2014). Furthermore, six prospective studies investigate ADRs (Donaldson and Norbeck, 2013;Ho et al, 2014;Thorne et al, 2014;Beyer-Westendorf et al, 2015;Monteagudo et al, 2015;Chan et al, 2016), one study investigate persistence (Martinez et al, 2016), and two investigate adherence (Gorst-Rasmussen et al, 2015;Hu et al, 2015).…”